MedTrace Logo

Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients

NCT03755193 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-09-21

No results posted yet for this study

Summary

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in Japanese osteoporosis patients after 2-year-denosumab therapy:

SERM and eldecalcitol treatment for 24 months Bisphosphonates and eldecalcitol treatment for 24 months Eldecalcitol treatment for 24 months

Conditions

Interventions

DRUG

SERM "Viviant®Tablet 20mg" and ELD "Edirol®Tablet 0.75ug"

To examine the effects of SERM and ELD in osteoporosis patients

DRUG

Bisphosphonates and ELD "Edirol®Tablet 0.75ug"

To examine the effects of BP and ELD in osteoporosis patients

DRUG

ELD "Edirol®Tablet 0.75ug"

To examine the effects of ELD in osteoporosis patients

Sponsors & Collaborators

  • Shinshu University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-24
Primary Completion
2024-11-23
Completion
2026-11-23

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03755193 on ClinicalTrials.gov